针对前列腺特异性膜抗原 (PSMA) 的治疗诊断代表了前列腺癌护理的一种新的靶向方法，该方法结合了诊断和治疗放射性药物来诊断和治疗该疾病。正电子发射断层扫描 (PET) 是首选的成像方法，几种用于量化 PSMA 的诊断放射性药物已获得 FDA 批准并投入临床使用。 [68Ga]Ga-PSMA-11 就是这样一种显像剂，也是本文的重点。一种 β 发射放射性配体疗法 ([177Lu]Lu-PSMA-617) 也已获得 FDA 批准用于前列腺癌治疗，其他几种 α 和 β 发射放射性配体疗法正在临床试验中。针对前列腺癌男性的 PSMA 治疗诊断讨论的重点是使用 [68Ga]Ga-PSMA-11 对患有前列腺癌的男性 PSMA 阳性病变进行成像。该审查涵盖 [68Ga]Ga-PSMA-11 制造、当前监管状态、[68Ga]Ga-PSMA-11 与其他成像技术的比较、临床更新以及 [68Ga]Ga-PSMA-11 人工智能的新兴应用PET.[68Ga]Ga-PSMA-11 与 PET/CT 扫描结合使用，对前列腺癌男性的 PSMA 阳性病变进行成像。它是由发生器或回旋加速器中的 68Ga 螯合前体制造的，并已获得世界各地监管部门的批准。它在临床上广泛与[177Lu]Lu-PSMA-617等放射性配体疗法结合使用。

Theranostics targeting prostate-specific membrane antigen (PSMA) represent a new targeted approach for prostate cancer care that combines diagnostic and therapeutic radiopharmaceuticals to diagnose and treat the disease. Positron emission tomography (PET) is the imaging method of choice and several diagnostic radiopharmaceuticals for quantifying PSMA have received FDA approval and are in clinical use. [68Ga]Ga-PSMA-11 is one such imaging agent and the focus of this article. One beta-emitting radioligand therapy ([177Lu]Lu-PSMA-617) has also received FDA approval for prostate cancer treatment, and several other alpha- and beta-emitting radioligand therapies are in clinical trials.Theranostics targeting PSMA in men with prostate cancer are discussed with a focus on use of [68Ga]Ga-PSMA-11 for imaging PSMA-positive lesions in men with prostate cancer. The review covers [68Ga]Ga-PSMA-11 manufacture, current regulatory status, comparison of [68Ga]Ga-PSMA-11 to other imaging techniques, clinical updates, and emerging applications of artificial intelligence for [68Ga]Ga-PSMA-11 PET.[68Ga]Ga-PSMA-11 is used in conjunction with a PET/CT scan to image PSMA positive lesions in men with prostate cancer. It is manufactured by chelating precursor with68Ga, either from a generator or cyclotron, and has regulatory approval around the world. It is widely used clinically in conjunction with radioligand therapies like [177Lu]Lu-PSMA-617.